TB Research

Mixed lichenoid and psoriasiform drug eruption induced by rifampicin

Xia Feng, Xin Ye, Jixiang Xu, Changqiang Li

Australasian Journal of Dermatology · 2019-12

Abstract

Rifampicin is an essential first line anti-tuberculosis drug. However, several cases of adverse reactions associated with this drug have been reported, the most common of which are cutaneous drug reactions. We report a case of mixed lichenoid and psoriasiform drug eruption induced by rifampicin.

MeSH terms

  • Medicine
  • Rifampicin
  • Drug eruption
  • Dermatology
  • Drug
  • Drug reaction
  • Tuberculosis
  • First line
  • Ethambutol
  • Pharmacology